{
    "Trade/Device Name(s)": [
        "Livongo Blood Glucose Monitoring System (BG1000)"
    ],
    "Submitter Information": "Livongo Health, Inc.",
    "510(k) Number": "K200277",
    "Predicate Device Reference 510(k) Number(s)": [
        "K181527"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "June 4, 2020",
    "Summary Letter Received Date": "May 4, 2020",
    "Submission Date": "May 2, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Livongo Blood Glucose Meter (BG1000)"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric electrochemical"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strip",
        "Control Solution",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for Livongo Blood Glucose Monitoring System (BG1000) for self-monitoring blood glucose in capillary whole blood using an amperometric electrochemical method.",
    "Indications for Use Summary": "For quantitative measurement of glucose in fresh capillary whole blood from the fingertips for self-testing by people with diabetes at home as an aid to monitor effectiveness of diabetes control programs; for single-patient use and not intended for diagnosis or screening of diabetes or use on neonates.",
    "fda_folder": "Clinical Chemistry"
}